Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial

医学 支气管肺泡灌洗 耐受性 愤怒(情绪) 肺 肺功能测试 炎症 免疫学 药理学 哮喘 慢性阻塞性肺病 糖基化 促炎细胞因子 呼吸道疾病 吸入 免疫系统 受体 肺动脉高压 内科学 药代动力学 临床试验
作者
Mark O’Carroll,David I. Kasahara,John Huetsch,Taylor Reed,Timothy N. Perkins,Rong Zhou,Lindsey Moser,Bianca R. Tomasini-Johansson,Anh Ta,Tim D. Oury,Tao Pei,James Hamilton,Erik W. Bush,Nicholas James Leeper,Matthias A. Salathe,John Blakely,Adrian Barnett,Eung Gu Lee,Sang Heon Kim,YongChul Lee
出处
期刊:Nature Medicine [Nature Portfolio]
卷期号:32 (9): 3339-3350 被引量:2
标识
DOI:10.1038/s41591-026-04607-z
摘要

The receptor for advanced glycation end products (RAGE), a multiligand receptor that is abundantly expressed by lung alveolar type-1 cells, amplifies and sustains the innate immune response in a variety of pulmonary disorders, including asthma and chronic obstructive pulmonary disease. Here we developed ARO-RAGE, an inhaled, lung-epithelium-targeted siRNA directed against pulmonary RAGE mRNA. Preclinical data from rat models of asthma, chronic obstructive pulmonary disease and acute lung injury, as well as mouse models for assessment of inflammatory responses, demonstrated deep and durable silencing of RAGE, limiting pulmonary inflammation. In macaques, ARO-RAGE produced dose-dependent reductions in membrane-bound RAGE levels in lung tissue and soluble RAGE (sRAGE) levels in serum; moreover, bronchoalveolar lavage showed post-dose decreases in sRAGE levels, consistent with robust silencing of lung membrane-bound RAGE. We then tested ARO-RAGE in a phase 1/2a, randomized, double-blinded, placebo-controlled trial designed to assess safety and tolerability (primary endpoint), pharmacokinetics (secondary endpoint) and pharmacodynamics (exploratory endpoint). In healthy volunteers (total n = 58, male n = 14) and in patients with asthma (total n = 19, male n = 6), inhaled ARO-RAGE was safe and well tolerated. No clinically relevant changes in chest x-ray findings, pulmonary function tests or systemic markers of inflammation were observed in the two cohorts. Plasma levels of ARO-RAGE were low, consistent with drug retention in the lung and minimal systemic bioavailability. Prolonged dose-responsive decreases in serum and bronchoalveolar lavage sRAGE levels indicated effective pulmonary target engagement. Together, these results demonstrate safe pulmonary delivery and target engagement of an inhaled, epithelial-targeted therapeutic siRNA, and support continued clinical development of ARO-RAGE. ClinicalTrials.gov registration: NCT05276570 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英姑的应助被lijunjun采纳,获得10
1秒前
MX完成签到,获得积分10
1秒前
lulu发布了新的文献求助30
1秒前
香蕉觅云的应助被Mr_龙在天涯采纳,获得10
1秒前
2秒前
2秒前
2秒前
4秒前
4秒前
jy完成签到,获得积分10
5秒前
shelter完成签到,获得积分10
5秒前
多情天荷完成签到,获得积分10
5秒前
开放灭绝完成签到,获得积分10
6秒前
6秒前
无极微光的应助被梅花采纳,获得20
6秒前
7秒前
思源的应助被xueee采纳,获得10
7秒前
所所的应助被Adamcssy19采纳,获得100
7秒前
maoning完成签到,获得积分10
7秒前
8秒前
yerong发布了新的文献求助10
8秒前
万能图书馆的应助被zhuzihao采纳,获得10
9秒前
不停发布了新的文献求助10
10秒前
10秒前
10秒前
Ting发布了新的文献求助10
10秒前
10秒前
花花完成签到,获得积分10
10秒前
小奇完成签到,获得积分10
11秒前
田様的应助被Jsl采纳,获得10
11秒前
裴依菲完成签到,获得积分10
11秒前
黎明发布了新的文献求助10
12秒前
12秒前
传奇3的应助被小安采纳,获得10
13秒前
妮子发布了新的文献求助10
13秒前
14秒前
云馨完成签到,获得积分0
14秒前
欢呼的过客完成签到,获得积分10
14秒前
自由的诗兰完成签到,获得积分10
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153573
求助须知:如何正确求助?哪些是违规求助? 9550279
关于积分的说明 21697424
捐赠科研通 7742161
什么是DOI,文献DOI怎么找? 3425546
关于科研通互助平台的介绍 2550636
邀请新用户注册赠送积分活动 2469181